Clinical Trial Update: Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating hydroxychloroquine with aldesleukin in metastatic renal cell carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Aldesleukin (interleukin-2)
• Hydroxychloroquine (hydroxychloroquine)

Snippet

Sponsor: Leonard Appleman | Conditions: Metastatic Renal Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-09-25